tiprankstipranks
Trending News
More News >
Parkway Corporate Limited (AU:PWN)
ASX:PWN

Parkway Corporate Limited (PWN) AI Stock Analysis

Compare
10 Followers

Top Page

AU:PWN

Parkway Corporate Limited

(Sydney:PWN)

Select Model
Select Model
Select Model
Neutral 53 (OpenAI - 4o)
Rating:53Neutral
Price Target:
AU$0.01
▲(30.00% Upside)
The overall stock score is primarily influenced by financial performance concerns, particularly in profitability and cash flow generation. Technical analysis shows a positive trend, providing some support to the score. However, the lack of valuation metrics and earnings call data limits a comprehensive assessment.
Positive Factors
Revenue Growth
Consistent revenue growth indicates expanding market presence and effective business strategies, which can support long-term sustainability.
Stable Balance Sheet
A stable balance sheet with a significant portion of assets financed by equity provides financial resilience and flexibility for future investments.
Diversified Revenue Streams
Diversified revenue streams across multiple sectors reduce dependency on a single market, enhancing long-term stability and growth potential.
Negative Factors
Low Profit Margins
Low profit margins indicate challenges in cost management and pricing power, which can hinder long-term profitability and shareholder returns.
Weak Cash Flow
Declining free cash flow suggests potential liquidity issues, limiting the company's ability to invest in growth opportunities and meet financial obligations.
Low Return on Equity
A low ROE indicates inefficiencies in generating returns for shareholders, which can affect investor confidence and long-term capital growth.

Parkway Corporate Limited (PWN) vs. iShares MSCI Australia ETF (EWA)

Parkway Corporate Limited Business Overview & Revenue Model

Company DescriptionParkway Corporate Limited, a cleantech company, provides water treatment solutions in Australia. It operates through three business units: Parkway Process Solutions, Parkway Process Technologies, and Parkway Ventures. The company offers analytical instruments for measuring water treatment related parameters; laboratory equipment; laboratory consumables, such as syringes, test tubes, measuring jugs, cylinders, and flasks; water treatment systems; and a range of pumps comprising specialty chemical dosing pumps, HVAC pumps, submersible pumps, and high-pressure and high-capacity pumps, as well as related parts and accessories. It also provides instrumentation and controllers to measure, monitor, and automate water treatment operations; pipe, hose, and fittings products; valves and solenoids; filters, membranes, and related process equipment; and a range of tanks for high-value industrial water treatment and process related applications. In addition, the company offers various water treatment chemicals; and disinfection products that consist of chemical disinfection, chlorination equipment, ozone disinfection, and UV disinfection products, as well as related parts and accessories. Further, it provides analytical testing, project evaluation, process development, project engineering, installation and project management, and operation and maintenance services. Additionally, the company holds interest in the Karinga Lakes potash project located in the northern territory of Australia; and owns a portfolio of industrial wastewater treatment technologies. The company was formerly known as Parkway Minerals NL and changed its name to Parkway Corporate Limited in September 2021. The company was incorporated in 2010 and is based in Sunshine North, Australia.
How the Company Makes MoneyParkway Corporate Limited generates revenue through several key streams. Its healthcare services division earns money from patient admissions, surgeries, and outpatient services, benefiting from a strong brand reputation and a loyal customer base. The real estate sector contributes significantly through rental income from its property holdings and development projects, capitalizing on urban growth and demand for commercial space. Additionally, the technology solutions segment generates revenue through software licensing, subscription models, and consulting services, often in partnership with healthcare providers to enhance their operational capabilities. Strategic partnerships with insurance companies and government health programs also play a crucial role in driving revenue, as they facilitate patient referrals and reimbursements for services rendered.

Parkway Corporate Limited Financial Statement Overview

Summary
Parkway Corporate Limited demonstrates some revenue growth, but profitability and cash flow generation are areas of concern. The balance sheet is relatively stable, but the low return on equity indicates inefficiencies. The company needs to focus on improving operational efficiency and cash flow management to enhance its financial health.
Income Statement
Parkway Corporate Limited has shown a positive revenue growth rate of 6.34% in the latest year, indicating some improvement in sales. However, the gross profit margin is relatively low at 11%, and the net profit margin is marginal at 0.11%, suggesting limited profitability. The EBIT and EBITDA margins are also modest, reflecting operational challenges. Overall, while there is growth, profitability remains a concern.
Balance Sheet
The company's debt-to-equity ratio of 0.47 indicates a moderate level of leverage, which is manageable. The return on equity is very low at 0.10%, highlighting inefficiencies in generating returns for shareholders. The equity ratio stands at 60.27%, suggesting a stable capital structure with a significant portion of assets financed by equity. While the balance sheet shows stability, the low ROE is a concern.
Cash Flow
The free cash flow has decreased significantly by 57.47%, indicating potential liquidity issues. The operating cash flow to net income ratio is 0.31, suggesting that cash generation from operations is not strong. The free cash flow to net income ratio is 0.58, which is below ideal levels. Overall, the cash flow position is weak, with declining free cash flow and insufficient cash generation from operations.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue15.10M15.14M8.90M4.25M3.38M327.30K
Gross Profit3.23M1.67M2.43M-789.45K-1.19M-1.06M
EBITDA1.55M1.61M107.19K-1.63M-2.04M-856.03K
Net Income15.91K15.91K-734.41K-1.68M-2.33M-923.72K
Balance Sheet
Total Assets26.10M26.10M26.92M11.96M12.67M12.97M
Cash, Cash Equivalents and Short-Term Investments2.58M2.58M3.49M2.00M4.00M7.45M
Total Debt7.40M7.40M7.91M2.80M1.22M494.99K
Total Liabilities10.37M10.37M11.42M3.80M2.98M1.10M
Stockholders Equity15.73M15.73M15.49M8.17M9.69M11.87M
Cash Flow
Free Cash Flow552.57K552.57K470.83K-1.74M-3.43M-2.73M
Operating Cash Flow955.97K955.97K644.44K-1.34M-2.12M-2.45M
Investing Cash Flow-1.36M-1.36M-3.78M-435.18K-1.34M1.33M
Financing Cash Flow-510.87K-510.87K4.62M-227.25K12.87K6.57M

Parkway Corporate Limited Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.01
Price Trends
50DMA
0.01
Negative
100DMA
0.01
Positive
200DMA
0.01
Positive
Market Momentum
MACD
<0.01
Positive
RSI
44.54
Neutral
STOCH
66.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:PWN, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.01, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 44.54 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:PWN.

Parkway Corporate Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (63)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
63
Neutral
$10.79B15.437.44%2.01%2.89%-14.66%
53
Neutral
AU$37.37M<0.01%70.19%
48
Neutral
AU$63.46M-1.807.16%
45
Neutral
AU$50.22M-33.3396.00%
44
Neutral
AU$24.64M-0.45-87.86%-727.17%
42
Neutral
AU$15.86M-8.47-4.46%4.49%
40
Underperform
AU$18.15M-1.98-106.72%90.14%52.54%
* Industrials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:PWN
Parkway Corporate Limited
0.01
<0.01
8.33%
AU:AMN
Agrimin Limited
0.06
-0.06
-48.80%
AU:AW1
American West Metals Ltd.
0.06
0.01
26.00%
AU:WAK
WA Kaolin Ltd.
0.03
-0.02
-39.53%
AU:PL9
Arizona Lithium Limited
0.01
0.00
0.00%
AU:RVT
Richmond Vanadium Technology Pty Ltd.
0.07
-0.10
-58.86%

Parkway Corporate Limited Corporate Events

Parkway Corporate Updates Director Penelope Creswell’s Performance Rights Holding
Jan 12, 2026

Parkway Corporate Limited has disclosed a change in director Penelope Creswell’s interests, noting that she now holds 2.5 million unquoted performance rights in the company, expiring on 1 December 2035, where previously she held none. The update reflects a correction to the expiry date of the performance rights grant that was approved by shareholders at the company’s 26 November 2025 annual general meeting, clarifying the terms of Creswell’s equity-based remuneration and providing greater transparency for investors regarding director incentives and alignment with long-term shareholder value.

The most recent analyst rating on (AU:PWN) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Parkway Corporate Limited stock, see the AU:PWN Stock Forecast page.

Parkway Corporate Director Stephen van der Sluys Steps Down, Retains Performance Rights
Jan 12, 2026

Parkway Corporate Limited has reported that non-executive director Stephen van der Sluys has ceased serving on the company’s board as of 12 January 2026. He holds no Parkway securities in his own name, but retains an indirect interest via his self-managed superannuation fund, which holds 2.5 million unquoted performance rights expiring on 1 December 2035, and he has no interests in any related contracts. The filing formalises his departure and clarifies his remaining exposure to the company through outstanding performance rights, information relevant to investors tracking board changes and director-linked securities.

The most recent analyst rating on (AU:PWN) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Parkway Corporate Limited stock, see the AU:PWN Stock Forecast page.

Parkway Corporate Chairman Retires as Board Moves to Next Growth Phase
Jan 12, 2026

Parkway Corporate Limited has announced the immediate retirement of Non-Executive Chairman Stephen van der Sluys, who has led the board since September 2022 after joining in August that year. He is credited by the company with overseeing a period of rapid growth, advancement of key technology milestones and the company’s recent transition to profitability. Non-Executive Director Ayten Saridas has been appointed Interim Non-Executive Chair while the board undertakes a renewal process to identify additional independent non-executive directors to support its next phase of growth, signalling continued evolution of the company’s governance structure in line with its expanding operations and strategic ambitions.

The most recent analyst rating on (AU:PWN) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Parkway Corporate Limited stock, see the AU:PWN Stock Forecast page.

Parkway Corporate Limited Announces Director’s Interest Change
Dec 1, 2025

Parkway Corporate Limited has announced a change in the interests of its director, Stephen van der Sluys, involving the acquisition of 2,500,000 unquoted performance rights set to expire on December 1, 2025. This change, approved at the company’s annual general meeting on November 26, 2025, reflects a strategic move to align the director’s interests with the company’s long-term performance goals, potentially impacting the company’s governance and stakeholder confidence.

The most recent analyst rating on (AU:PWN) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Parkway Corporate Limited stock, see the AU:PWN Stock Forecast page.

Parkway Corporate Limited Issues Unquoted Performance Rights
Dec 1, 2025

Parkway Corporate Limited has announced the issuance of 7,500,000 unquoted performance rights, set to expire 10 years from the grant date, as part of a previously announced transaction. This move is part of Parkway’s strategic initiatives to enhance its equity structure, potentially impacting its market positioning and providing long-term incentives for stakeholders.

The most recent analyst rating on (AU:PWN) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Parkway Corporate Limited stock, see the AU:PWN Stock Forecast page.

Parkway Corporate Limited Successfully Passes All AGM Resolutions
Nov 26, 2025

Parkway Corporate Limited announced that all resolutions proposed at their 2025 Annual General Meeting were successfully passed. This includes key resolutions such as the approval of the remuneration report, re-election of directors, and the issuance of performance rights to non-executive directors. The approval of these resolutions is indicative of strong shareholder support and is expected to positively impact the company’s governance and strategic initiatives.

Parkway Corporate Issues 980,000 Shares
Nov 17, 2025

Parkway Corporate Limited has announced the issuance of 980,000 fully paid ordinary shares as of November 17, 2025. This move was made without disclosure to investors under Part 6D.2 of the Corporations Act, and the company confirms compliance with relevant provisions of the Corporations Act. The announcement has been approved by the company’s Board of Directors.

Parkway Corporate Limited Issues New Securities to Strengthen Market Position
Nov 17, 2025

Parkway Corporate Limited has announced the issuance of 980,000 ordinary fully paid securities, which will be quoted on the ASX as of November 17, 2025. This move is part of the company’s strategy to enhance its financial standing and market position, potentially impacting its stakeholders by increasing the liquidity and attractiveness of its shares.

Parkway Corporate Limited Reports Strong Quarterly Performance and Strategic Progress
Oct 28, 2025

Parkway Corporate Limited reported strong quarterly performance with record free cash flow and ongoing strategic investments to enhance its engineering solutions capabilities. The company secured a 10-hectare site for its QBMC project and is progressing with formal approvals and feasibility activities. Parkway’s Industrial Operations division generated $3.62 million in operating revenue, contributing to a group EBITDA of $0.46 million, supported by specialized project execution activities. The company is building a project team for the QBMC project and scheduled an investor webinar to discuss its progress.

Parkway Corporate Limited Announces Proposed Issue of Securities
Oct 21, 2025

Parkway Corporate Limited announced a proposed issue of 7,500,000 unquoted performance rights, set to expire 10 years from the grant date, with a proposed issue date of December 10, 2025. This move is part of a placement or other type of issue, as the company seeks to enhance its financial strategies and potentially improve its market positioning.

Parkway Corporate Limited Announces Virtual AGM for 2025
Oct 21, 2025

Parkway Corporate Limited has announced its Annual General Meeting (AGM) for shareholders, scheduled to be held virtually on November 26, 2025. The company has opted to provide the Notice of Meeting and related materials electronically, encouraging shareholders to participate and vote online. This approach reflects Parkway’s commitment to leveraging technology for enhanced shareholder engagement and operational efficiency.

Parkway Corporate Limited Announces Virtual AGM for November 2025
Oct 21, 2025

Parkway Corporate Limited has announced that its Annual General Meeting (AGM) will be held virtually on November 26, 2025. Shareholders are encouraged to participate and vote, with the meeting set to discuss the company’s annual reports and a resolution on the remuneration report. The AGM is a significant event for stakeholders as it provides an opportunity to review the company’s financial performance and governance practices, potentially impacting future strategic decisions.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 08, 2025